Stockscreener 앱 받기
2.03
4.25%
-0.09
시간 외 거래:
1.94
-0.09
-4.43%
전일 마감가:
$2.12
열려 있는:
$2.05
하루 거래량:
230.02K
Relative Volume:
0.04
시가총액:
$6.79M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.3306
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
-11.35%
1개월 성능:
-6.02%
6개월 성능:
+232.79%
1년 성능:
-28.01%
1일 변동 폭
$1.7614
$2.06
1주일 범위
$1.7614
$2.37
52주 변동 폭
$0.16
$6.83
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.03 | 6.79M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks
BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz
BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World
BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com Australia
BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com
BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India
Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Yahoo Finance
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - Marketscreener.com
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN
BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia
BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com
BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks
BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire
Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan
BioXcel Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BioXcel Therapeutics raises $14M in direct offering - Hartford Business Journal
Building Materials Stocks Q4 In Review: Sherwin-Williams (NYSE:SHW) Vs Peers - The Globe and Mail
Top Penny Stocks To Watch NowFebruary 28th - MarketBeat
Bioxcel Therapeutics Announces Closing Of $14 Million Registered Direct Offering -March 04, 2025 at 04:50 pm EST - Marketscreener.com
BioXcel Therapeutics, Inc. Closes $14 Million Registered Direct Offering of Common Stock and Warrants - Nasdaq
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewswire
How Will BioXcel's $14M Offering Impact Shareholders? Key Details on BTAI's Latest Financing - StockTitan
3 Penny Stocks to Watch Now, 3/4/25 - TipRanks
Stock Market Update – BioXcel Therapeutics Stock Price Prediction 2025 - ldccbank
Sector Update: Health Care -March 03, 2025 at 03:51 pm EST - Marketscreener.com
BioXcel Therapeutics announces $14M registered direct offering - TipRanks
BioXcel Therapeutics, Inc. Secures $14 Million in Registered Direct Offering of Common Stock and Warrants - Nasdaq
BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewswire
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):